Prudential Financial Inc. lessened its holdings in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 82.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 39,229 shares of the biotechnology company’s stock after selling 180,586 shares during the period. Prudential Financial Inc. owned 0.20% of Enanta Pharmaceuticals worth $2,778,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of ENTA. Vanguard Group Inc increased its stake in Enanta Pharmaceuticals by 30.1% in the 3rd quarter. Vanguard Group Inc now owns 1,426,791 shares of the biotechnology company’s stock worth $121,934,000 after buying an additional 330,374 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Enanta Pharmaceuticals by 30.1% during the third quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after purchasing an additional 330,374 shares in the last quarter. Matarin Capital Management LLC purchased a new position in shares of Enanta Pharmaceuticals during the third quarter valued at about $17,964,000. BlackRock Inc. grew its position in shares of Enanta Pharmaceuticals by 6.5% during the third quarter. BlackRock Inc. now owns 2,590,166 shares of the biotechnology company’s stock valued at $221,354,000 after purchasing an additional 157,166 shares in the last quarter. Finally, Teachers Advisors LLC grew its position in shares of Enanta Pharmaceuticals by 249.0% during the third quarter. Teachers Advisors LLC now owns 107,124 shares of the biotechnology company’s stock valued at $9,155,000 after purchasing an additional 76,426 shares in the last quarter. Institutional investors and hedge funds own 86.20% of the company’s stock.
Shares of Enanta Pharmaceuticals stock opened at $101.24 on Friday. The stock has a market cap of $1.97 billion, a PE ratio of 29.09 and a beta of 1.39. Enanta Pharmaceuticals Inc has a twelve month low of $64.08 and a twelve month high of $127.77.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Wednesday, February 6th. The biotechnology company reported $1.25 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.46 by ($0.21). Enanta Pharmaceuticals had a net margin of 36.19% and a return on equity of 22.78%. The firm had revenue of $69.89 million for the quarter, compared to analysts’ expectations of $71.27 million. During the same quarter in the previous year, the business earned $0.59 EPS. The company’s revenue for the quarter was up 83.4% on a year-over-year basis. As a group, sell-side analysts forecast that Enanta Pharmaceuticals Inc will post 1.51 EPS for the current year.
In related news, Director Bruce L. A. Carter sold 1,546 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $99.16, for a total value of $153,301.36. Following the completion of the transaction, the director now owns 1,546 shares of the company’s stock, valued at approximately $153,301.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Yat Sun Or sold 27,684 shares of the stock in a transaction dated Monday, February 11th. The shares were sold at an average price of $89.39, for a total transaction of $2,474,672.76. Following the completion of the transaction, the vice president now directly owns 320,169 shares of the company’s stock, valued at approximately $28,619,906.91. The disclosure for this sale can be found here. In the last ninety days, insiders sold 59,514 shares of company stock valued at $5,632,849. 11.35% of the stock is owned by insiders.
A number of research analysts have recently weighed in on the company. Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. BidaskClub upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, November 20th. Finally, TheStreet lowered Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, November 26th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Enanta Pharmaceuticals currently has an average rating of “Hold” and an average target price of $100.00.
WARNING: This news story was first reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2019/03/17/prudential-financial-inc-has-2-78-million-holdings-in-enanta-pharmaceuticals-inc-enta.html.
Enanta Pharmaceuticals Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Featured Article: What Are Treasury Bonds?
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.